- Home
- DIAX vs CRMD Comparison
DIAX vs CRMD Comparison
Compare DIAX & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DIAX | CRMD |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | US |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.9M | 605.9M |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | DIAX | CRMD |
|---|---|---|
| Price | $15.68 | $7.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 94.8K | ★ 2.0M |
| Earning Date | 01-01-0001 | 04-10-2026 |
| Dividend Yield | ★ 7.93% | N/A |
| EPS Growth | N/A | ★ 67.03 |
| EPS | N/A | ★ 1.97 |
| Revenue | N/A | ★ $43,472,170.00 |
| Revenue This Year | N/A | $627.64 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.65 |
| Revenue Growth | N/A | ★ 66363.08 |
| 52 Week Low | $12.42 | $5.60 |
| 52 Week High | $15.85 | $17.43 |
Technical Indicators
Market Signals| Indicator | DIAX | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 56.68 | 36.70 |
| Support Level | $15.22 | $7.29 |
| Resistance Level | $15.76 | $7.74 |
| Average True Range (ATR) | 0.17 | 0.37 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 69.84 | 8.97 |
Price Performance
Historical ComparisonAbout DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.